Acumen Pharmaceuticals Q2 net loss widens

Acumen Pharmaceuticals

12/08/2025 12:10

Overview

Acumen Q2 net loss widens to $41.0 mln, driven by increased R&D expenses

Cash reserves of $166.2 mln expected to support operations into early 2027

Outlook

Cash reserves expected to support operations into early 2027

Result Drivers

SCREENING INNOVATIONS - Co implemented a two-step screening process in ALTITUDE-AD phase 2 clinical trial, reducing costs by 40% across U.S. and Canadian sites and improving enrollment rates

R&D EXPENSES - Increased R&D expenses driven by manufacturing and materials costs for ALTITUDE-AD trial

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$40.95 mln
Q2 Basic EPS
-$0.68
Q2 Income From Operations
-$41.75 mln
Q2 Operating Expenses
$41.75 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $10.00, about 85.8% above its August 11 closing price of $1.42

Press Release: ID:nGNX6js0Qq

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)